Skip to content

Real-world study on safety evaluation of 30,000 cases of Lobaplatin for injection after marketing

Real-world study on safety evaluation of 30,000 cases of Lobaplatin for injection after marketing

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044341
Enrollment
Unknown
Registered
2021-03-16
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

LBP:IncludeLBP protocol

Sponsors

Chongqing University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients who have been pathologically or clinically diagnosed as malignant tumors and are scheduled to receive the LBP regimen; 2) Completely follow the real medical procedures, and evaluate the patient's age, gender, comorbidities, primary tumor type,Pathological types, clinical stages, number of chemotherapy lines, chemotherapy regimens and chemotherapy methods were not uniformly prescribed.

Exclusion criteria

Exclusion criteria: 1) Pregnant or lactating women, women who were preparing for pregnancy within 6 months before enrollment; 2) Subjects who have participated in investigational drug/device clinical trials within 4 weeks before enrollment; 3) For other reasons, the researcher considers it unsuitable to participate in the study.

Design outcomes

Primary

MeasureTime frame
safety;

Secondary

MeasureTime frame
Characteristics of users;Clinical characteristics of drug use;Quality of life changes before and after treatment;

Countries

China

Contacts

Public ContactYongzhong Wu

Chongqing University Cancer Hospital

gcp6552@163.com+86 021-65310288

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026